"They have just got OUT of the Covid antibody business. And now they watch Ellumehealth pocket 230 million dollars for going INTO the Covid antigen business".
Ellume obviously gave the subject more thought and didn't simply act in a reactionary (or speculatory) manner. One of the two know what they are doing - whilst I suspect there is a lesson to be learnt for the other one.
Ann: Cellmid Publishes Data on Novel Proprietary FGF5 Aptamer, page-12
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AN1 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $2.768M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2852402 | 0.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.7¢ | 2617059 | 3 |
View Market Depth
| Last trade - 16.12pm 18/06/2024 (20 minute delay) ? |
| AN1 (ASX) Chart |
Day chart unavailable